Home LiteratureArticle Details
PMID: 8129746 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.

Biochemical pharmacology ·Vol. 47 ·No. 4 ·1994-02-11 ·Pages 689-97

Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, Hamilton TC

Abstract

A series of cisplatin-resistant cell lines were used to examine the formation and removal of platinum-DNA adducts from the overall genome and the formation and removal of cisplatin-interstrand cross-links from specific genomic regions. Cisplatin accumulation and DNA platination levels, which correlated linearly, were similar in three of the resistant cell lines despite differences in their primary cisplatin resistance. Increased platinum removal from total genomic DNA was found to be associated with increased resistance. Interstrand cross-link levels were found to be 2- to 4-fold lower in the 28S ribosomal RNA gene and a non-coding genomic region of the resistant cell lines as compared with the parental A2780 cell line. In addition, 1.2- to 2.7-fold more cross-links were formed in the non-coding region than in the ribosomal RNA gene in all of the cell lines. Interstrand cross-links were removed more rapidly from both regions of the highly cisplatin-resistant C80 and C200 cells and from the ribosomal RNA gene only in the cell lines of lower resistance. The results support a role for DNA repair and alterations in interstrand cross-link formation in cisplatin resistance and provide evidence for heterogeneous interstrand cross-link formation in the genome.

MeSH Terms
Cisplatin/metabolism,pharmacology DNA/metabolism DNA Repair Drug Resistance Female Humans Ovarian Neoplasms/drug therapy Platinum/metabolism RNA, Ribosomal/genetics Time Factors Tumor Cells, Cultured/drug effects
Chemicals
RNA, Ribosomal Platinum DNA Cisplatin
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Johnson S W
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111.
Perez R P
Godwin A K
Yeung A T
Handel L M
Ozols R F
Hamilton T C
Article Info
Journal
Biochemical pharmacology
Abbr.
Biochem Pharmacol
ISSN
0006-2952
Published
1994-02-11
Pages
689-97
Language
English
Region
England
NLM ID
0101032
Subset
IM
Grants
NCI NIH HHS · CA06927 · United States
NCI NIH HHS · CA51228 · United States
NCI NIH HHS · CA52181 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com